Pharma Equity Group A/S (OCSE:PEG) Sloan Ratio % : 0.00% (As of Mar. 2024)

Pharma Equity Group A/S Sloan Ratio % Chart

Pharma Equity Group A/S Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Sloan Ratio %		Get a 7-Day Free Trial					-19.54	-	-	-	-9.73

Pharma Equity Group A/S Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Sloan Ratio %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Pharma Equity Group A/S's Sloan Ratio %

For the Biotechnology subindustry, Pharma Equity Group A/S's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Equity Group A/S's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Sloan Ratio % falls into.

Pharma Equity Group A/S Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Pharma Equity Group A/S's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Pharma Equity Group A/S's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Pharma Equity Group A/S's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -4.346 (Jun. 2023 ) + -4.393 (Sep. 2023 ) + -13.007 (Dec. 2023 ) + -7.17 (Mar. 2024 ) = kr-28.92 Mil.
Pharma Equity Group A/S's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -6.008 (Jun. 2023 ) + -2.672 (Sep. 2023 ) + -4.036 (Dec. 2023 ) + -7.828 (Mar. 2024 ) = kr-20.54 Mil.
Pharma Equity Group A/S's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) + 0 (Mar. 2024 ) = kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group A/S  (OCSE:PEG) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Pharma Equity Group A/S has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

Pharma Equity Group A/S Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Equity Group A/S (OCSE:PEG) Business Description